To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter focuses on the challenges presented by therapeutic targets in the central nervous system (CNS), the manner in which animal models have and can be used to support the translation of therapeutic biologies to the human CNS, the blood brain barrier (BBB), and the uncertainties of CNS drug exposures. It also addresses how these challenges can be met and the associated risks of CNS therapeutic development mitigated. Animal CNS disease models are unique tools that have led to a significant increase in the number of potential new therapeutic targets and an improved understanding of the biologies underlying disease processes. Development of pharmacodynamic (Pd) biomarkers for CNS drug development should be a high priority. Pd biomarkers are used in Phase 1, 2, and 3 studies, although most commonly in Phase 1 and 2 studies.
Email your librarian or administrator to recommend adding this to your organisation's collection.